Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators

Affiliations

• ¹ Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
• ² Icelandic Medicines Agency, Reykjavík, Iceland; Landspitali - The National University Hospital of Iceland, Reykjavík, Iceland.
• ³ Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Lithuanian State Medicines Control Agency, Kaunas, Lithuana.
• ⁴ German Federal Institute for Drugs and Medical Devices, Bonn, Germany.
• ⁵ European Medicines Agency, Amsterdam, the Netherlands.
• ⁶ European Medicines Agency, Amsterdam, the Netherlands. Electronic address: thorsten.vetter@ema.europa.eu.